Literature DB >> 32417157

Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma.

Melissa A Reimers1, Robert S Figenshau2, Eric H Kim2, Julie Tucker3, Nicole Kasten3, Adeel S Khan4, Jan M Hanneken3, Zachary L Smith2, James J Hsieh5.   

Abstract

Entities:  

Keywords:  Frontline therapy; Kidney cancer; Stage 4; Surgery; Systemic therapy

Year:  2020        PMID： 32417157      PMCID： PMC7541406          DOI： 10.1016/j.clgc.2020.04.002

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  18 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.

Authors:  Anas M Saad; Mohamed M Gad; Muneer J Al-Husseini; Inas A Ruhban; Mohamad Bassam Sonbol; Thai H Ho
Journal:  Clin Genitourin Cancer       Date:  2018-10-11       Impact factor: 2.872

Review 3.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

4.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

5.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

6.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Authors:  Axel Bex; Astrid A M van der Veldt; Christian Blank; Alfons J M van den Eertwegh; Epie Boven; Simon Horenblas; John Haanen
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

8.  First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.

Authors:  Fernando Sabino M Monteiro; Andrey Soares; Márcio Debiasi; Fabio A Schutz; Fernando Cotait Maluf; Diogo Assed Bastos; Andre Sasse; Carolina G S Cauduro; Gabriela Oliveira Mendes; Patricia K Ziegelmann; André P Fay
Journal:  Clin Genitourin Cancer       Date:  2020-03-04       Impact factor: 2.872

9.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

10.  Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Authors:  Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777
View more
  2 in total

Review 1.  Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.

Authors:  Alexandre Ingels; Riccardo Campi; Umberto Capitanio; Daniele Amparore; Riccardo Bertolo; Umberto Carbonara; Selcuk Erdem; Önder Kara; Tobias Klatte; Maximilian C Kriegmair; Michele Marchioni; Maria C Mir; Idir Ouzaïd; Nicola Pavan; Angela Pecoraro; Eduard Roussel; Alexandre de la Taille
Journal:  Nat Rev Urol       Date:  2022-05-11       Impact factor: 16.430

2.  Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab.

Authors:  Michikata Hayashida; Yuji Miura; Taisho Noda; Taro Yamanaka; Naoto Tanaka; Shotaro Yasuoka; Suguru Oka; Kazushige Sakaguchi; Keiichi Kinowaki; Shinji Urakami
Journal:  IJU Case Rep       Date:  2022-04-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.